What were the pyrilutamide Phase 3 results?

Kintor reported that KX-826 met its primary endpoint in a 666-patient, 24-week, vehicle-controlled Phase 3 trial in China: roughly +15.3 hairs/cm2 from baseline at the 1.0% twice-daily dose, about +10.65 hairs/cm2 over placebo (p<0.0001), with no drug-related serious adverse events. It is company-reported top-line data from a China-only trial, a real result that still deserves caution.

When will pyrilutamide be released as an approved drug?

There is no approved pyrilutamide product anywhere. Any regulatory approval would come first in China via Kintor, and no confirmed approval or launch date exists. Treat any specific 'release date' you read as speculation.

What is pyrilutamide's half-life?

No reliable published human pharmacokinetic numbers exist in the public domain. KX-826 was designed as a topical with rapid systemic clearance (the point is high local receptor occupancy with minimal systemic exposure), but a precise human half-life figure would be invented if we quoted one.

Is pyrilutamide stronger than RU-58841?

Per molecule, yes. Its androgen receptor binding is very potent (IC50 reported around 0.28 nM), which is why it is used at 0.5% against RU-58841's 5%. Whether that translates to better results on a scalp is unresolved: there has never been a head-to-head study.

Koshine is Kintor Pharmaceutical's consumer brand name for pyrilutamide (KX-826). Koshine-826 was made available in China's Hainan Bo'ao Lecheng pilot zone on a restricted basis. Koshine, KX-826, and pyrilutamide are the same molecule; there is no approved version of it in the UK, EU, or US.

Can I buy pyrilutamide in the UK?

Norwood Labs supplies pyrilutamide (KX-826) 0.5% strictly as a laboratory research reference material, not for human use. A published sample report identifies sample 41276. It does not establish a human safety or efficacy profile.

What Is Pyrilutamide (KX-826)? Explained, Trials to 2026

Q: Did pyrilutamide fail its US trial?

Kintor's May 2023 release on its 123-man US Phase 2 reported a statistically significant gain from baseline (about 10 hairs/cm2 at 0.5% twice daily, p=0.0088) but only said hair counts 'indicated an improvement' versus placebo, with no placebo-adjusted p value. The placebo-controlled primary comparison was not reported as significant. That gap, alongside the positive China Phase 3, is why the honest summary is 'promising but unsettled' rather than 'proven'.

Q: When will pyrilutamide be released as an approved drug?

There is no approved pyrilutamide product anywhere. Any regulatory approval would come first in China via Kintor, and no confirmed approval or launch date exists. Treat any specific 'release date' you read as speculation.

Q: What is pyrilutamide's half-life?

No reliable published human pharmacokinetic numbers exist in the public domain. KX-826 was designed as a topical with rapid systemic clearance (the point is high local receptor occupancy with minimal systemic exposure), but a precise human half-life figure would be invented if we quoted one.

Q: Is pyrilutamide stronger than RU-58841?

Per molecule, yes. Its androgen receptor binding is very potent (IC50 reported around 0.28 nM), which is why it is used at 0.5% against RU-58841's 5%. Whether that translates to better results on a scalp is unresolved: there has never been a head-to-head study.

Q: What is Koshine?

Koshine is Kintor Pharmaceutical's consumer brand name for pyrilutamide (KX-826). Koshine-826 was made available in China's Hainan Bo'ao Lecheng pilot zone on a restricted basis. Koshine, KX-826, and pyrilutamide are the same molecule; there is no approved version of it in the UK, EU, or US.

Q: Can I buy pyrilutamide in the UK?

Norwood Labs supplies pyrilutamide (KX-826) 0.5% strictly as a laboratory research reference material, not for human use. A published sample report identifies sample 41276. It does not establish a human safety or efficacy profile.

Key facts (as of October 2026)

Pyrilutamide (KX-826) is a topical androgen receptor antagonist developed by Kintor Pharmaceutical, with a reported AR IC50 of about 0.28 nM.
In March 2026 Kintor reported that a 666-patient, 24-week China Phase 3 met its primary endpoint, about 10.65 hairs/cm² over placebo at 1.0%.
The 123-man US Phase 2, reported in May 2023, gave a change-from-baseline figure (about 10 hairs/cm², p=0.0088) and no significant placebo-adjusted result.
No pyrilutamide product is approved for marketing in any country as of October 2026.
Kintor also runs GT20029, a topical androgen receptor degrader (PROTAC), as a sibling programme.
Norwood Labs' pyrilutamide powder batch 10237 was assayed before formulation, and a report for solution sample 41276 is published on the lab results page.

The short version

Pyrilutamide (KX-826) is a topical androgen receptor antagonist designed as a hair-loss drug by Kintor Pharmaceutical.
It is the only compound in this niche with human Phase 3 data: +10.65 hairs/cm² over placebo in a 666-patient China trial.
Its US Phase 2 (2023) never reported a significant placebo-adjusted result, only a gain from baseline. The evidence is promising, not settled.
In-vitro receptor binding and formulation concentrations cannot establish relative human efficacy or safety.
Not approved anywhere. Research use only.

What pyrilutamide actually is

Pyrilutamide, research code KX-826, branded by Kintor as Koshine, is a small-molecule androgen receptor (AR) antagonist from Kintor Pharmaceutical (Suzhou, China), a topical candidate for androgenetic alopecia and acne. Unlike RU-58841, it has trial data. As of October 2026 it is not approved as a medicine anywhere, and its binding data do not establish safety for human use.

Kintor also runs a sibling programme, GT20029, a topical AR degrader (PROTAC) that removes the receptor rather than blocking it. That distinction matters mostly as context: KX-826 is the conventional antagonist of the two.

How it works

The mechanism is the same androgen-receptor blockade described in our RU-58841 overview: dihydrotestosterone (DHT) drives follicle miniaturisation by binding the AR in susceptible follicles, and an antagonist that occupies the receptor without activating it interrupts the signal locally. Pyrilutamide's distinguishing feature is potency: reported AR binding around IC50 ≈ 0.28 nM in an assay. This cannot predict outcomes in people; the products' different labelled concentrations are not dosing guidance.

The clinical record, both halves of it

China Phase 3: the positive result

In March 2026 Kintor reported that KX-826 met its primary endpoint in a 666-patient, 24-week, randomised, vehicle-controlled Phase 3 in Chinese men with androgenetic alopecia: about +15.3 hairs/cm² from baseline at the 1.0% twice-daily dose, roughly +10.65 hairs/cm² over placebo (p<0.0001), with no drug-related serious adverse events reported. For a niche whose favourite compound (RU-58841) has zero completed trials, this is the single strongest piece of human evidence that exists.

US Phase 2: the gap

The other half is less quotable and more important than most vendor pages admit. Kintor's May 2023 release on the 123-man US Phase 2 reported a significant change from baseline at 0.5% twice daily (about 10 hairs/cm2, p=0.0088) but said only that counts "indicated an improvement" versus placebo, with no placebo-adjusted p value. The placebo-controlled primary comparison was never reported as statistically significant, which is why the community treats it as a miss. Different population, different dosing arms, and a shorter programme, but an unreported placebo result is still a gap. Combined with the fact that the Phase 3 numbers are company-reported top-line data from a China-only trial, the honest scientific position is: a genuinely promising molecule whose efficacy is indicated, not established.

"When is it coming out?"

There is no confirmed release date, and no approved pyrilutamide product exists anywhere as of October 2026. Kintor has said it plans to file in China following the March 2026 Phase 3 result, so any first approval would come there. No US Phase 3 has started. Until a regulator approves it, the compound exists only as a research material.

Not on any confirmed date. There is no approved pyrilutamide product anywhere in the world. If approval comes, it will come first in China through Kintor's own programme. Every "release date" floating around forums is extrapolation. In the meantime the compound exists only as a research chemical, which is the capacity in which we supply it, with no treatment claims attached.

Tolerability and what users report

Trial adverse-event reports concern investigational formulations under trial conditions, not this research material. Community reports about irritation or results are uncontrolled and cannot establish safety or efficacy. Long-term controlled safety data are insufficient.

Quality: the same trap as RU

Pyrilutamide is harder to source as a raw material than RU-58841 and more expensive per gram, which raises the incentive to underdose it. The defence is identical: batch-specific, publicly verifiable analysis of the finished solution. Our pyrilutamide powder (batch 10237) was independently assayed before formulation, the weigh-in corrected by its purity. A report for solution sample 41276 is published on the lab results page. That report does not identify the currently supplied batch.

Shop

Pyrilutamide (KX-826) 0.5%

Research reference only.

View product →

The honest caveats

Pyrilutamide is not a licensed medicine. Its positive trial data is company-reported and China-only; its US Phase 2 reported no significant placebo-adjusted result. Norwood Labs supplies it strictly for laboratory research use and makes no medical claims. For the full comparison against the other compound in this niche, read RU-58841 vs Pyrilutamide.

What Is Pyrilutamide (KX-826)? A Research Overview